Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-07-07T06:28:09.922Z Has data issue: false hasContentIssue false

46 - Cerebral palsy: advances in definition, classification, management, and outcome

from Section 6 - Assessing outcome of the brain-injured infant

Published online by Cambridge University Press:  12 January 2010

David K. Stevenson
Affiliation:
Stanford University School of Medicine, California
William E. Benitz
Affiliation:
Stanford University School of Medicine, California
Philip Sunshine
Affiliation:
Stanford University School of Medicine, California
Susan R. Hintz
Affiliation:
Stanford University School of Medicine, California
Maurice L. Druzin
Affiliation:
Stanford University School of Medicine, California
Get access

Summary

Overview

Cerebral palsy (CP) is a neurodevelopmental disorder. It begins in early childhood and is a lifelong condition. Core features include abnormal movement and posture due to impairments in coordination and/or muscle tone. CP is not an etiologic diagnosis. Rather, it is a descriptive term based on an individual's clinical picture. Among children diagnosed with CP, there is great heterogeneity with respect to etiology, type of impairment, and severity of impairment. Brain disturbances that lead to CP may occur prenatally, perinatally, or in the young child during brain development and maturation. Although the brain disturbances leading to CP are not progressive, the clinical picture is not static. Clinical features of CP evolve with time, development, learning, motor training, and therapy. The disorder can potentially lead to poor growth of a limb, contractures and poor range of motion, pain secondary to spasticity, inability to complete voluntary movements, neglect of a limb, inability to complete activities of daily living, and poor participation in the community.

CP is the most common cause of physical disability in children. Based on classic definitions for the disorder, 2–3/1000 live births are affected by CP. The prevalence of CP is 77/1000 children for those born less than 28 weeks gestation and 40/1000 in children born between 28 and 31 weeks gestation. The total lifetime costs for those born with CP in the USA in the year 2000 will be $11.5 billion, based on the 2003 dollar value.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blair, E, Watson, L. Epidemiology of cerebral palsy. Semin Fetal Neonatal Med 2006; 11: 117–25.CrossRefGoogle ScholarPubMed
Himmelmann, K, Hagberg, G, Beckung, E, et al. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995–1998. Acta Paediatr 2005; 94: 287–94.CrossRefGoogle ScholarPubMed
Honeycutt, A, Dunlap, L, Chen, H, et al. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. MMWR Morb Mortal Wkly Report 2004; 53: 57–9.Google Scholar
Mac Keith, RC, MacKenzie, ICK, Polani, PE. The Little Club. Memorandum on terminology and classification of “cerebral palsy.” Cereb Palsy Bull 1959; 1: 27–35.Google Scholar
Bax, MCO. Terminology and classification of cerebral palsy. Dev Med Child Neurol 1964; 6: 295–307.CrossRefGoogle ScholarPubMed
Rosenbaum, P, Paneth, N, Leviton, A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8–14.Google ScholarPubMed
,World Health Organization. International Classification of Functioning, Disability and Health. Geneva: World Health Organization, 2001.
Baxter, P, Rosenbloom, L. CP or not CP?Dev Med Child Neurol 2005; 47: 507.CrossRefGoogle ScholarPubMed
Carr, LJ. Definition and classification of cerebral palsy. Dev Med Child Neurol 2005; 47: 508–10.CrossRefGoogle ScholarPubMed
Palisano, R, Rosenbaum, P, Walter, S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214–23.CrossRefGoogle ScholarPubMed
Eliasson, AC, Krumlinde-Sundholm, L, Rosblad, B, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006; 48: 549–54.CrossRefGoogle ScholarPubMed
Ashwal, S, Russman, BS, Blasco, PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62: 851–63.CrossRefGoogle Scholar
Boyd, RN, Morris, ME, Graham, HK.Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8: 150–66.CrossRefGoogle ScholarPubMed
Butler, C, Darrah, J. Effects of neurodevelopmental treatment (NDT) for cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2001; 43: 778–90.CrossRefGoogle Scholar
Reddihough, DS, King, J, Coleman, G, et al. Efficacy of programmes based on Conductive Education for young children with cerebral palsy. Dev Med Child Neurol 1998; 40: 763–70.CrossRefGoogle ScholarPubMed
Wiley, ME, Damiano, DL. Lower-extremity strength profiles in spastic cerebral palsy. Dev Med Child Neurol 1998; 40: 100–7.CrossRefGoogle ScholarPubMed
Damiano, DL, Kelly, , Vaughan, CL. Effects of quadriceps femoris muscle strengthening on crouch gait in children with spastic diplegia. Phys Ther 1995; 75: 658–71.CrossRefGoogle ScholarPubMed
Damiano, DL, Abel, MF. Functional outcomes of strength training in spastic cerebral palsy. Arch Phys Med Rehabil 1998; 79: 119–25.CrossRefGoogle ScholarPubMed
Willis, JK, Morello, A, Davie, A, et al. Forced use treatment of childhood hemiparesis. Pediatrics 2002; 110: 94–6.CrossRefGoogle ScholarPubMed
Gordon, AM, Charles, J, Wolf, SL. Efficacy of constraint-induced movement therapy on involved upper-extremity use in children with hemiplegic cerebral palsy is not age-dependent. Pediatrics 2006; 117: e363–73.CrossRefGoogle Scholar
Eliasson, AC, Krumlinde-Sundholm, L, Shaw, K, et al. Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model. Dev Med Child Neurol 2005; 47: 266–75.CrossRefGoogle Scholar
Taub, E, Miller, NE, Novack, TA, et al. Technique to improve chronic motor deficit after stroke. Arch Phys Med Rehabil 1993; 74: 347–54.Google ScholarPubMed
Wolf, SL, Lecraw, , Barton, , et al. Forced use of hemiplegic upper extremities to reverse the effect of learned nonuse among chronic stroke and head-injured patients. Exp Neurol 1989; 104: 125–32.CrossRefGoogle ScholarPubMed
Wolf, SL, Winstein, CJ, Miller, JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 2006; 296: 2095–104.CrossRefGoogle ScholarPubMed
Taub, E, Ramey, SL, DeLuca, S, et al. Efficacy of constraint-induced movement therapy for children with cerebral palsy with asymmetric motor impairment. Pediatrics 2004; 113: 305–12.CrossRefGoogle ScholarPubMed
Deluca, SC, Echols, K, Law, CR, et al. Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial. J Child Neurol 2006; 21: 931–8.CrossRefGoogle ScholarPubMed
Sutcliffe, TL, Gaetz, WC, Logan, WJ, et al. Cortical reorganization after constraint-induced movement therapy in pediatric cerebral palsy. J Child Neurol 2007; 22: 1281–7.CrossRefGoogle Scholar
Charles, J, Gordon, AM. Development of hand-arm bimanual intensive training (HABIT) for improving bimanual coordination in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006; 48: 931–6.CrossRefGoogle ScholarPubMed
Hazelwood, ME, Brown, JK, Rowe, PJ, et al. The use of therapeutic electrical stimulation in the treatment of hemiplegic cerebral palsy. Dev Med Child Neurol 1994; 36: 661–73.CrossRefGoogle Scholar
McLaughlin, J, Bjornson, K, Temkin, N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002; 44: 17–25.CrossRefGoogle ScholarPubMed
Mittal, S, Farmer, JP, Al-Atassi, B, et al. Long-term functional outcome after selective posterior rhizotomy. J Neurosurg 2002; 97: 315–25.CrossRefGoogle ScholarPubMed
Gul, SM, Steinbok, P, McLeod, K. Long-term outcome after selective posterior rhizotomy in children with spastic cerebral palsy. Pediatr Neurosurg 1999; 31: 84–95.CrossRefGoogle ScholarPubMed
Farmer, JP, Sabbagh, AJ. Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy. Childs Nerv Syst 2007; 23: 991–1002.CrossRefGoogle ScholarPubMed
Matthew, A, Matthew, MC. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005; 51: 109–13.CrossRefGoogle Scholar
Matthew, A, Matthew, MC. Bedtime diazepam enhances well-being in children with spastic cerebral palsy. Pediatr Rehabil 2005; 8: 63–6.CrossRefGoogle Scholar
Linder-Lucht, M, Kirschner, J, Herrmann, J, et al. Why do children with cerebral palsy discontinue therapy with botulinum toxin A?Dev Med Child Neurol 2006; 48: 319–20.CrossRefGoogle ScholarPubMed
Fehlings, D, Rang, M, Glazier, J, et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331–7.CrossRefGoogle ScholarPubMed
Corry, IS, Cosgrove, AP, Walsh, EG, et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39: 185–93.CrossRefGoogle ScholarPubMed
Baker, R, Jasinski, M, Maciag-Tymecka, I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44: 666–75.CrossRefGoogle ScholarPubMed
Reddihough, DS, King, JA, Coleman, GJ, et al. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 2002; 44: 820–7.CrossRefGoogle ScholarPubMed
Ubhi, T, Bhakta, BB, Ives, HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 481–7.CrossRefGoogle ScholarPubMed
Naumann, MJJ. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20: 981–90.CrossRefGoogle ScholarPubMed
Bakheit, AM, Severa, S, Cosgrove, A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001; 43: 234–8.CrossRefGoogle ScholarPubMed
Tilton, AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol 2003; 18: S50–66.CrossRefGoogle ScholarPubMed
Albright, AL, Ferson, SS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21: e3.CrossRefGoogle ScholarPubMed
Russell, DJ, Rosenbaum, PL, Cadman, DT, et al. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989; 31: 341–52.CrossRefGoogle ScholarPubMed
Rosenbaum, PL, Walter, SD, Hanna, SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA 2002; 288: 1357–63.CrossRefGoogle ScholarPubMed
Strauss, DJ, Shavelle, RM, Anderson, TW. Life expectancy of children with cerebral palsy. Pediatr Neurol 1998; 18: 143–9.CrossRefGoogle ScholarPubMed
Blair, E, Watson, L, Badawi, N, et al. Life expectancy among people with cerebral palsy in Western Australia. Dev Med Child Neurol 2001; 43: 508–15.CrossRefGoogle ScholarPubMed
Turk, MA, Scandale, J, Rosenbaum, PF, et al. The health of women with cerebral palsy. Phys Med Rehabil Clin N Am 2001; 12: 153–68.Google ScholarPubMed
Liptak, GS, Accardo, PJ. Health and social outcomes of children with cerebral palsy. J Pediatr 2004; 145: S36–41.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×